STOCK TITAN
  1. Home
  2. ICVX

Icosavax (ICVX) Stock Price, News & Analysis

ICVX NASDAQ

Company Description

Icosavax (NASDAQ: ICVX) is classified in the biological product (except diagnostic) manufacturing industry within the Manufacturing sector.

This page collects what Stock Titan holds for ICVX, including price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.

Stock Performance

Chart
$—
0.00%
0.00
Last updated:
-
Performance 1 year
$0.0
Market Cap
50.1M
Shares outstanding

Latest News

View All
—

Frazier Life Sciences Adds Industry Veteran and Serial Dealmaker, Adam Simpson, to Company Creation Team

+49.48%

AstraZeneca to Acquire Icosavax, Including Potential First-in-class RSV and hMPV Combination Vaccine With Positive Phase II Data

acquisition clinical trial
+49.48%

Icosavax, Inc. Announces Agreement to be Acquired by AstraZeneca

acquisition
+49.48%

Icosavax Announces Positive Topline Interim Phase 2 Results for Combination VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older Adults

clinical trial
+14.81%

Icosavax Reports Third Quarter 2023 Financial Results and Provides Corporate Update

earnings
+1.52%

Icosavax to Participate in the Jefferies London Healthcare Conference

conferences

Icosavax has 10 recent news articles. Of the recent coverage, 7 articles coincided with positive price movement and 2 with negative movement. Key topics include acquisition, clinical trial, earnings, conferences. View all ICVX news →

SEC Filings

View All

No SEC filings available for ICVX.

Financial Highlights

—
Revenue (TTM)
—
Net Income (TTM)
—
Diluted EPS (TTM)
—
Operating Cash Flow
—
Net Profit Margin
—
Oper. Profit Margin

Upcoming Events

Short Interest History

Last 12 Months

Days to Cover History

Last 12 Months

ICVX Company Profile & Sector Positioning

Icosavax (ICVX) operates in the Biological Product (except Diagnostic) Manufacturing industry within the broader Manufacturing sector and is listed on the NASDAQ.